Back to Newsroom

BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today reported data demonstrating the efficacy and tolerability of BIND’s Accurin platform with multiple anti-cancer agents. These data, which were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston, November 5-9, 2015, describe the ability of Accurins to control the biodistribution of therapeutic payloads across multiple active anti-cancer agents, pathways and targets, which results in either improved efficacy, tolerability or both.

Read more here.